Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
Terheyden, P., Weishaupt, C., Heinzerling, L., Klinkhardt, U., Krauss, J., Mohr, P., Kiecker, F., Becker, J.C., Dähling (Submitter, A., Döner, F., Heidenreich, R., Scheel, B., Schönborn-Kellenberger, O., Seibel, T., Gnad-Vogt, U.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1305TiPPhase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
Terheyden, P, Weishaupt, C, Heinzerling, L, Klinkhardt, U, Krauss, J, Mohr, P, Kiecker, F, Becker, J C, Dähling (Submitter, A, Döner, F, Heidenreich, R, Scheel, B, Schönborn-Kellenberger, O, Seibel, T, Gnad-Vogt, U
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article